A research team can have millions of patient records in front of them and still be stuck. What they need is technically in there somewhere. But it is scattered across systems, written a dozen different ways, or missing in the one spot. So the study stalls before it even begins.
That gap, between having real-world records and having something you can actually study, is what people are talking about when they use the term "research-ready."
Research-ready real-world data is health information that has been cleaned, standardized, checked for quality, and organized so that a research team can trust the results it produces. Getting to that point is a process, and it is what turns a pile of records into credible evidence.
Sidus Insights works with providers to prepare exactly this kind of data, drawing on a de-identified resource of more than 10 billion data points that supports biopharma, payers, and academic researchers. This guide walks through what makes data research-ready, why most records are not ready straight out of the box, and how to tell when yours are.
Real-world data (RWD) is health information that gets collected during everyday care and daily operations. It is not created for studying. It builds naturally as patients get diagnosed, treated, and billed.
Common sources include:
Electronic health records from clinics and health systems
Insurance and billing claims
Pharmacy and prescription records
Lab and test results
Disease registries
All of this data is powerful because it reflects what actually happens in real care, across large groups of people. That is exactly why researchers, biopharma teams, and payers want to use it.
The catch is simple. This data was never built to answer a research question. It was built to help treat patients and process payments. So before anyone can rely on it for evidence, it needs work.
Think of raw health data like ingredients scattered across a kitchen. Everything you need might be there, but it is spread out, labeled differently, and some of it is missing.
Here are the usual problems:
The same thing is written in many different ways across different systems.
Some records have gaps, because a detail was never entered.
Data comes in different formats that do not line up neatly.
It is unclear where a piece of information came from or how it was recorded.
None of this makes the data "bad." It just means the data is not ready yet. Getting it ready is a process, and that process is what turns a pile of records into something a research team can trust.
When data is not ready, the cost is not just wasted time. Studies built on messy or ill-fitting records can point in the wrong direction, and decisions get made on shaky ground. That matters because these decisions are big ones: which treatments get studied, how safe a therapy looks once it is in wide use, and where health gaps are hiding.
Getting the data right up front is what lets researchers, biopharma teams, and payers act with confidence instead of guessing. So what does "ready" actually look like?
There is a common myth that health data is either good quality or bad quality. The truth is more useful than that. Data quality is not a single grade. It depends on the question you are trying to answer.
That said, research-ready data usually shares the same core qualities. Here are the main ones, in plain terms.
This is the most important one. Data that is perfect for one study can be useless for another. The right question is not "Is this data good?" It is "Is this data right for what I want to learn?"
Case example: same data, two very different questions A research team wants to compare two diabetes medicines to see which one keeps blood sugar under control better over a year. A dataset that tracks prescriptions, lab values, and follow-up visits over time fits that question well.
Now a different team wants to study how many people quit a medicine because of side effects. If that same dataset rarely records the reason a prescription stopped, it is no longer a good fit. The data has not changed. The question has.
Matching the data to the question is step one every time.
Every real-world dataset has gaps. The goal is not perfection. The goal is having enough of the right information for your specific question.
If you are studying a treatment, you need reasonable records of who received it, when, and what happened next. A few missing fields may not matter. Large gaps in the exact area you are studying can quietly bias your results, so this is worth checking early.
Research-ready data has been checked for errors and stray values that do not make sense. Consistency matters too. The same condition, drug, or test should be recorded the same way across records, so the numbers add up correctly when you group people together.
Different health systems record the same thing in different ways. One clinic might write a diagnosis with one code, and another might use a different label for the exact same condition.
Research-ready data is standardized. That means all of this variety has been mapped to one shared system, often called a common data model. Once data speaks one language, you can combine records from many sources and compare them fairly. Without this step, you are comparing apples to oranges without knowing it.
A single snapshot rarely answers a health question. Most research needs to see what happened before a treatment, during it, and after it.
Data that tracks the same de-identified patient journeys over months and years is far more valuable than scattered one-time records. This is what lets researchers study outcomes, not just single moments.
Case study: a 12-year look at who gets new treatments first Researchers at Indiana University School of Medicine, working with Sidus Insights, asked whether lower-income patients got a new class of blood-thinning medicines (NOACs) as quickly as higher-income patients after these drugs reached the market in 2010.
Using a de-identified dataset from 2010 to 2022, they compared about 101,900 lower-income patients with 89,100 higher-income ones, using Census income data by zip code. In the first three years, lower-income patients received the medicines at only 0.65 times the rate of higher-income patients, a gap that took until 2013 to close.
A study like this only works with research-ready data: a long time window, a large de-identified population, and records that link cleanly to outside sources.
Trustworthy data comes with a clear history. Researchers should be able to see where each piece of information came from and how it was processed along the way. This is called provenance. It is what lets others check the work and repeat the study, which is the backbone of credible evidence.
Research-ready data is de-identified. That means it describes patterns across large, aggregate groups of people at the population or cohort level, not any single identifiable patient. Strong privacy protection is not an add-on. It is a basic requirement for using health data responsibly and legally.
Before starting a study, it helps to run through a short list. If you can answer yes to most of these, your data is likely research-ready for the question at hand:
Does the data actually cover what my question is about?
Is it complete enough in the specific area I care about?
Has it been checked for accuracy and consistency?
Is everything standardized so records from different sources line up?
Can I follow de-identified patients over the time period I need?
Can I trace where the data came from?
Is patient privacy fully protected?
If several answers are no, the data is not unusable. It usually just needs more preparation, or it may be the wrong dataset for this particular question.
Research-ready data is less about size and more about readiness. The best evidence does not come from the biggest pile of records. It comes from data that has been prepared with care, standardized, checked, and matched to the right question.
At Sidus Insights, we focus on exactly that: turning complex, real-world healthcare data into de-identified, research-ready insights that biopharma teams, payers, and researchers can rely on to make confident decisions.